Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0793
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2638
    +0.0016 (+0.13%)
     
  • USD/JPY

    151.2400
    -0.1320 (-0.09%)
     
  • Bitcoin USD

    70,099.87
    -1,260.29 (-1.77%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

UPDATE 1-US judge hearing fight over Amgen deal for Horizon eyes September trial

(Adds details on when ruling is expected in paragraph two; background in paragraphs 3 and 4)

CHICAGO, May 23 (Reuters) - The judge who will decide if Amgen can go forward with its $27.8 billion purchase of Horizon Therapeutics on Tuesday said he was considering an evidentiary hearing on the matter in September.

Judge John Kness said he would likely take about four weeks after the hearing ends to make a ruling. The case is being heard in federal court in Chicago.

The Federal Trade Commission

filed a lawsuit

on May 16 aimed at stopping the transaction in a rare move to block a large pharmaceutical deal.

The FTC said it opposed the deal because of concerns Amgen would leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers to give favorable terms for Horizon's two key products - the fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa.

(Reporting by David Thomas; Writing by Diane Bartz; Editing by Mark Porter)

Advertisement